Advertisement

Topics

Orexigen Axes 40 Percent of Workforce After FDA Turns Down Obesity Drug

18:18 EST 9 Feb 2011 |

No surprise here, the axe has fallen at San Diego-based Orexigen Therapeutics. Orexigen (NASDAQ: OREX) said today it has eliminated 23 jobs, or about 40 percent of its workforce, a little more than a week after the FDA shot down Orexigen’s application to start selling its first product, a new drug for obesity. The company [...]

Original Article: Orexigen Axes 40 Percent of Workforce After FDA Turns Down Obesity Drug

NEXT ARTICLE

More From BioPortfolio on "Orexigen Axes 40 Percent of Workforce After FDA Turns Down Obesity Drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Obesity
Obesity is the condition in which excess fat has accumulated in the body (mostly in subcutaneous tissues). clinical obesity is considered to be present when a person has a BMI of over 30 (Oxford Dictionary of Medicine). It is becoming increasing common i...